IMMUNOLOGICAL MONITORING IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA TREATED REGIMENS USING ALEMTUZUMAB
The last decade was marked by the advent and wide clinical use of novel chemo-(fludara) and immunotherapies on the basis of monoclonal antibodies. The aim of this study was to immunological monitoring some B-, T-and NKmarkers of B-CLL patients during treatment regimens using alemtuzumab. Different lymphocyte subsets (CD19, CD20, CD22, FMC7, CD23, CD5, CD38, CD3+, CD3/CD4, CD3/CD8,CD3-CD16+CD56+,CD3+CD16+56+, CD3+HLA-DR +, CD4+/25+) contents were determined in peripheral blood of 10 patients with B-CLL by 4-color flow cytometry. The data obtained showed that the 8 patients developed clinical and hematological remission associated with significantly increased number of NK-, CD3+HLA-DR+cells and with low number of immunoregulatory CD3+CD4+ lymphocytes.